On that date, Ilham Kadri will officially succeed Jean-Pierre Clamadieu, who will then relinquish his executive duties and his mandate as director of Solvay. Ilham Kadri will join Solvay on January 1, 2019 and spend two months transitioning with Jean-Pierre Clamadieu, before taking the leadership role and continuing Solvay’s transformation strategy. Ilham Kadri is CEO and President of U.S. hygiene technology and services company Diversey and has led, since 2013, its turnaround, carve-out and divestment to a private equity fund. She brings to Solvay her vast international experience having worked for top multinationals like Shell-Basell, UCB-Cytec, Huntsman and Dow Chemical across the United States, Europe, the Middle East and in Asia.
“Solvay’s Board of Directors unanimously approved the selection of Ilham Kadri as head of the Solvay Group. Her knowledge of our strategic markets, strongly customer-focused mindset and her capacities to build a galvanizing vision make her the leader that the Group needs to accelerate its cultural transformation and unleash its growth potential. She can count on a solid and experienced Solvay management team to fulfill this mission,” said Nicolas Boël, Chairman of the Board of Directors of Solvay.
“I wish to thank the Board of Directors for its confidence in me. I’m looking forward to join the Group whose passion for science, its values and transformation echo my own personal and professional journey. Early next year, I will work alongside Solvay’s teams to accelerate value creation based on innovation, collaboration, a customer centric culture and a clear sense of purpose. These fundamentals will guide my actions at Solvay,” said Ilham Kadri.
A holder of Moroccan and French nationalities, Ilham Kadri has an engineering degree from the European School of Chemistry, Polymers and Materials Science in Strasbourg, France, and a PhD in macromolecular physico-chemistry from Louis Pasteur University in Strasbourg.
By: Globe Newswire
Corteva (Indianapolis, Indiana) says it has signed a definitive agreement to acquire Stoller Group (Houston, Texas), a producer of biostimulants and plant nutrition products, for $1.2 billion. Stoller is one of the largest independent biologicals companies globally, with operations in more than 60 countries and more than $400 million in annual sales.
OMV has announced its new corporate structure today, designed to fully enable the delivery of Strategy 2030. The new organization will be built on five distinct areas. In addition to the CEO and CFO areas, three business segments will be established: Chemicals & Materials, Fuels & Feedstock, and Energy.
The European petchem sector is readying for some tough quarters. It’s a different picture in the US. So is this the best time ever to find a new role in the chemical industry? If you are in Europe, you would expect me to say probably not. But actually, it depends. So let me give you four answers to this question.